OPTIMAS CAPITAL Ltd Makes New Investment in Bristol Myers Squibb Company $BMY

OPTIMAS CAPITAL Ltd purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 255,500 shares of the biopharmaceutical company’s stock, valued at approximately $11,523,000. Bristol Myers Squibb accounts for approximately 7.3% of OPTIMAS CAPITAL Ltd’s holdings, making the stock its 3rd largest position.

Other institutional investors have also recently made changes to their positions in the company. CVA Family Office LLC lifted its stake in shares of Bristol Myers Squibb by 2.6% in the 3rd quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company’s stock valued at $404,000 after purchasing an additional 223 shares during the last quarter. Mccarter Private Wealth Services LLC raised its holdings in Bristol Myers Squibb by 5.0% in the 3rd quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company’s stock valued at $222,000 after buying an additional 235 shares during the period. Creative Financial Designs Inc. ADV lifted its position in Bristol Myers Squibb by 26.7% in the second quarter. Creative Financial Designs Inc. ADV now owns 1,123 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 237 shares during the last quarter. Center for Financial Planning Inc. lifted its position in Bristol Myers Squibb by 15.9% in the second quarter. Center for Financial Planning Inc. now owns 1,869 shares of the biopharmaceutical company’s stock valued at $87,000 after buying an additional 256 shares during the last quarter. Finally, Tilson Financial Group Inc. boosted its stake in Bristol Myers Squibb by 4.2% during the third quarter. Tilson Financial Group Inc. now owns 6,445 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 259 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $61.99 on Monday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The stock has a market capitalization of $126.20 billion, a PE ratio of 17.97, a PEG ratio of 0.19 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. The stock has a 50-day simple moving average of $54.34 and a 200-day simple moving average of $49.03.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 70.30% and a net margin of 14.64%.The firm had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same quarter in the previous year, the company posted $1.67 earnings per share. The firm’s quarterly revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.1%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date of this dividend was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 73.04%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BMY. UBS Group upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $46.00 to $65.00 in a report on Wednesday, January 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $57.00 price objective (up previously from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Finally, Guggenheim restated a “buy” rating and set a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday. Eight equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $59.20.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Q4 revenue beat and growth portfolio momentum — BMY reported $12.5B in Q4 revenue with growth in new products (immuno‑oncology) helping offset legacy declines; investors view the topline beat as validating the company’s transition. Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
• Positive Sentiment: Upside FY‑2026 guidance — management set FY‑2026 EPS of $6.05–$6.35 and revenue guidance of $46.0–$47.5B, both above consensus, which markets are treating as a material bullish catalyst for forward earnings and cash flow expectations. Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off
• Positive Sentiment: Management and pipeline commentary — CEO Chris Boerner highlighted the strongest pipeline in a decade and called out new growth engines, supporting investor confidence in sustained medium‑term revenue growth. Bristol Myers Squibb CEO: Richest product pipeline we’ve had in the last decade
• Positive Sentiment: Street reaction — Citigroup raised its price target from $60 to $64 (maintaining a neutral rating), signalling modest analyst support for upside after the print and guidance. Tickerreport: Citigroup raises target
• Neutral Sentiment: Dividend/total-return thesis discussed — commentary (Seeking Alpha) frames BMY as a dividend income play with hidden upside from pipeline and buybacks; relevant for income-oriented investors but less immediate as a price catalyst. Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026
• Negative Sentiment: EPS mix and legacy headwinds — non‑GAAP EPS dynamics and year‑over‑year decline in EPS (and some legacy drug declines) remain a risk; some outlets note EPS was below certain Street figures and that company sales may decline in 2026 before new-product gains fully offset legacy erosion. MarketBeat: Earnings and call materials
• Negative Sentiment: Some analysts/publication notes that overall sales could decline in 2026 — this has been flagged as a medium‑term headwind that could pressure consensus if new-product uptake lags expectations. MSN: Bristol Myers expects sales to decline this year

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.